Multiple cutaneous and hepatic infantile hemangiomas having a successful response to propranolol as monotherapy at neonatal period

R. Cavalli, V. Novotna, R. B. Buffon, C. Gelmetti

Research output: Contribution to journalArticlepeer-review

Abstract

Infantile hepatic hemangioma (IHH) is a common liver tumors of infancy with a higher incidence in females. Various treatments for infantile hepatic hemangioma such as systemic corticosteroids, interferon-alpha, vincristine and cyclophosphamide have been suggested, though no consensus exists about the first-choice treatment. Recent evidences suggest that propranolol, a nonselective β-blocker, may be effective and safe as first-line therapy for infantile hepatic hemangioma. We report a case of female bom at term with a weight of 2.450 g started to develop multiple cutaneous IHs at 10 days of age and presenting concomitant multiple cutaneous and hepatic infantile hemangiomas confirmed on magnetic resonance imaging. Propranolol, used as monotherapy, was started at 14 days of age at a dose of 2 mg/kg/day orally and maintained for 6 months. Patient was monitored in the hospital during first days of treatment with propranolol, and discharged after no side-effects were detected. Hepatic and cutaneous lesions had complete resolution in three months, although the fibro-fatty residuum of largest cutaneous nodule was still palpable at month 6. A further control after 6 months showed no recurrences. Our report case suggests that propranolol can be a safe and effective first-line therapy for neonates with concomitant multiple cutaneous and hepatic infantile hemangiomas.

Original languageEnglish
Pages (from-to)525-530
Number of pages6
JournalGiornale Italiano di Dermatologia e Venereologia
Volume148
Issue number5
Publication statusPublished - 2013

Keywords

  • Child
  • Hemangioma
  • Propranolol
  • Therapeutics

ASJC Scopus subject areas

  • Dermatology

Fingerprint Dive into the research topics of 'Multiple cutaneous and hepatic infantile hemangiomas having a successful response to propranolol as monotherapy at neonatal period'. Together they form a unique fingerprint.

Cite this